VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | An insight into how novel agents are influencing survival outcomes in patients with MF

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on survival outcomes in patients with myelofibrosis (MF) and how novel agents, such as JAK inhibitors, have improved patient quality of life and symptoms. Dr Masarova also explains the challenges with directly assessing survival outcomes and the need to obtain more detailed data from clinical trials. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter